View Older Stories View More Recent Stories

Oct 3, 2022 05:52AM Myovant Sciences (MYOV) Confirms Prelim $22.75/sh Acquisition Proposal
Oct 2, 2022 07:36PM Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
Oct 2, 2022 07:36PM Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
Sep 16, 2022 04:30PM Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Sep 16, 2022 10:37AM Myovant Recognizes Prostate Cancer Awareness Month with Educational Sponsorships and Online Campaign to Encourage Patients to Speak Up, Seek Support and Be Informed
Sep 7, 2022 10:03AM Urovant Sciences® Named 17th on the List of Fortune® Best Workplaces in BioPharma™ (2022)
Sep 2, 2022 06:45AM Myovant Sciences to Participate at Upcoming Investor Conferences
Aug 16, 2022 04:30PM Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Aug 5, 2022 08:50PM Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Aug 5, 2022 08:50PM Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Jul 27, 2022 04:05PM Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
Jul 27, 2022 04:05PM Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
Jul 18, 2022 04:30PM Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Jul 13, 2022 11:02AM The Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities in the U.S. Highlighted in New Survey
Jul 13, 2022 06:45AM Myovant Sciences to Host First Fiscal Quarter 2022 Earnings Conference Call at 5:00 p.m. Eastern Time on July 27, 2022
Jul 7, 2022 11:07AM Urovant Sciences® Named One of 2022 “Best Places to Work” in Orange County
Jul 5, 2022 08:05AM Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerlan
Jun 17, 2022 06:46AM Myovant Sciences (MYOV) and Pfizer (PFE) Announce Publication of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Jun 17, 2022 06:45AM Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Jun 17, 2022 06:45AM Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain
Jun 16, 2022 04:35PM Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Jun 3, 2022 06:50AM Myovant Sciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
Jun 2, 2022 06:51AM Myovant Sciences (MYOV), Pfizer (PFE) Announce FDA Acceptance of sNDA for MYFEMBREE®
Jun 2, 2022 06:50AM Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
Jun 2, 2022 06:50AM Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE®
May 15, 2022 10:05AM Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting
May 13, 2022 12:33PM Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Associa
May 10, 2022 08:00AM Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
May 10, 2022 08:00AM Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
May 10, 2022 06:55AM Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
May 10, 2022 06:55AM Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
May 9, 2022 06:30AM Myovant Sciences (MYOV), Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX for Advanced Hormone-Sensitive Prostate Cancer in Europe
May 9, 2022 06:30AM Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
May 9, 2022 06:30AM Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
May 6, 2022 06:45AM Myovant Sciences (MYOV) and Pfizer (PFE) Announce FDA Extended Review Period of sNDA for MYFEMBREE
May 6, 2022 06:45AM Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
May 6, 2022 06:45AM Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis
Apr 29, 2022 07:10PM Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
Apr 29, 2022 07:10PM Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
Apr 26, 2022 08:30AM Myovant Sciences to Host Fourth Fiscal Quarter and Fiscal Year 2021 Earnings Conference Call at 8:30 a.m. Eastern Time on May 10, 2022
Apr 26, 2022 08:03AM Phathom Pharmaceuticals (PHAT) Appoints Frank Karbe to its Board of Directors
Apr 26, 2022 08:00AM Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
Apr 26, 2022 08:00AM Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
Apr 25, 2022 01:15PM ALTAVANT SCIENCES TO PRESENT DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530
Apr 19, 2022 11:04AM Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA® in Dry and Wet Overactive Bladder Populations
Apr 13, 2022 12:02PM Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 20
Apr 12, 2022 05:43AM Myovant Sciences (MYOV) and Pfizer (PFE) Issues Update on sNDA for MYFEMBREE
Apr 12, 2022 12:00AM Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
Apr 12, 2022 12:00AM Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis
Apr 4, 2022 11:08AM Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officer
View More Recent Stories View Older Stories